Pacific Biosciences of California, Inc. (FRA:P09)
Germany · Delayed Price · Currency is EUR 2.021
-0.126 (-5.85%)
Last updated: Jan 28, 2026, 4:35 PM CET
FRA:P09 Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 154.58 | 154.01 | 200.52 | 128.3 | 130.51 | 78.89 | |
Revenue Growth (YoY) | -10.72% | -23.19% | 56.29% | -1.69% | 65.43% | -13.20% |
Cost of Revenue | 96.21 | 106.34 | 142.32 | 74.83 | 71.35 | 46.33 |
Gross Profit | 58.37 | 47.67 | 58.2 | 53.47 | 59.17 | 32.57 |
Selling, General & Admin | 157.98 | 175.02 | 169.82 | 160.85 | 124.12 | 72.8 |
Research & Development | 105.09 | 134.92 | 187.17 | 193 | 112.9 | 64.15 |
Amortization of Goodwill & Intangibles | 375.27 | 27.4 | 8.14 | 0.73 | 0.31 | - |
Other Operating Expenses | 1 | 1 | 3.44 | 3.71 | - | - |
Operating Expenses | 639.34 | 338.34 | 368.56 | 358.29 | 237.33 | 136.95 |
Operating Income | -580.97 | -290.66 | -310.37 | -304.82 | -178.16 | -104.39 |
Interest Expense | -7.97 | -13.41 | -14.34 | -14.69 | -12.53 | -0.27 |
Other Non Operating Income (Expenses) | 6.6 | 10.74 | 19.84 | 7.39 | 4.1 | 1.95 |
EBT Excluding Unusual Items | -582.35 | -293.34 | -304.86 | -312.12 | -186.59 | -102.7 |
Merger & Restructuring Charges | 4.1 | - | -9.04 | - | -83.13 | 34 |
Impairment of Goodwill | -51.3 | -144.5 | - | - | - | - |
Gain (Loss) on Sale of Investments | 6.29 | 13.04 | 12.84 | 0.24 | -4.01 | 0.11 |
Asset Writedown | -55 | -40 | - | - | - | - |
Other Unusual Items | 175.06 | 155.26 | -17.09 | -2.38 | -1.14 | 98 |
Pretax Income | -503.2 | -309.54 | -318.16 | -314.25 | -274.87 | 29.4 |
Income Tax Expense | 0.43 | 0.32 | -11.42 | - | -93.65 | - |
Net Income | -503.63 | -309.85 | -306.74 | -314.25 | -181.22 | 29.4 |
Net Income to Common | -503.63 | -309.85 | -306.74 | -314.25 | -181.22 | 29.4 |
Shares Outstanding (Basic) | 295 | 274 | 254 | 225 | 204 | 165 |
Shares Outstanding (Diluted) | 295 | 274 | 254 | 225 | 204 | 175 |
Shares Change (YoY) | 9.13% | 8.22% | 12.95% | 10.00% | 16.67% | 14.71% |
EPS (Basic) | -1.71 | -1.13 | -1.21 | -1.40 | -0.89 | 0.18 |
EPS (Diluted) | -1.71 | -1.13 | -1.21 | -1.40 | -0.89 | 0.17 |
Free Cash Flow | -126.26 | -212.25 | -268.02 | -279.96 | -117.11 | 18.46 |
Free Cash Flow Per Share | -0.43 | -0.77 | -1.06 | -1.25 | -0.57 | 0.11 |
Gross Margin | 37.76% | 30.95% | 29.02% | 41.68% | 45.33% | 41.28% |
Operating Margin | -375.83% | -188.73% | -154.78% | -237.58% | -136.51% | -132.31% |
Profit Margin | -325.80% | -201.18% | -152.97% | -244.93% | -138.85% | 37.27% |
Free Cash Flow Margin | -81.68% | -137.81% | -133.66% | -218.20% | -89.73% | 23.40% |
EBITDA | -192.6 | -249.48 | -290.64 | -294.43 | -170.58 | -97.96 |
EBITDA Margin | -124.59% | -161.98% | -144.94% | -229.47% | -130.70% | -124.16% |
D&A For EBITDA | 388.38 | 41.19 | 19.72 | 10.39 | 7.58 | 6.43 |
EBIT | -580.97 | -290.66 | -310.37 | -304.82 | -178.16 | -104.39 |
EBIT Margin | - | -188.73% | -154.78% | -237.58% | -136.51% | -132.31% |
Revenue as Reported | 154.58 | 154.01 | 200.52 | 128.3 | 130.51 | 78.89 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.